TY - JOUR
T1 - Amino terminal pro-B-type natriuretic peptide, secondary stroke prevention, and choice of antithrombotic therapy
AU - Longstreth, W. T.
AU - Kronmal, Richard A.
AU - Thompson, John L.P.
AU - Christenson, Robert H.
AU - Levine, Steven R.
AU - Gross, Rebecca
AU - Brey, Robin L.
AU - Buchsbaum, Richard
AU - Elkind, Mitchell S.V.
AU - Tirschwell, David L.
AU - Seliger, Stephen L.
AU - Mohr, J. P.
AU - De Filippi, Christopher R.
PY - 2013/3
Y1 - 2013/3
N2 - Background and Purpose-Because of its association with atrial fibrillation and heart failure, we hypothesized that amino terminal pro-B-type natriuretic peptide (NT-proBNP) would identify a subgroup of patients from the Warfarin-Aspirin Recurrent Stroke Study, diagnosed with inferred noncardioembolic ischemic strokes, where anticoagulation would be more effective than antiplatelet agents in reducing risk of subsequent events. Methods-NT-proBNP was measured in stored serum collected at baseline from participants enrolled in Warfarin-Aspirin Recurrent Stroke Study, a previously reported randomized trial. Relative effectiveness of warfarin and aspirin in preventing recurrent ischemic stroke or death over 2 years was compared based on NT-proBNP concentrations. Results-About 95% of 1028 patients with assays had NT-proBNP below 750 pg/mL, and among them, no evidence for treatment effect modification was evident. For 49 patients with NT-proBNP >750 pg/mL, the 2-year rate of events per 100 person-years was 45.9 for the aspirin group and 16.6 for the warfarin group, whereas for 979 patients with NT-proBNP ≤750 pg/mL, rates were similar for both treatments. For those with NT-proBNP >750 pg/mL, the hazard ratio was 0.30 (95% confidence interval: 0.12-0.84; P=0.021) significantly favoring warfarin over aspirin. A formal test for interaction of NT-proBNP with treatment was significant (P=0.01). Conclusions-For secondary stroke prevention, elevated NT-proBNP concentrations may identify a subgroup of ischemic stroke patients without known atrial fibrillation, about 5% based on the current study, who may benefit more from anticoagulants than antiplatelet agents.
AB - Background and Purpose-Because of its association with atrial fibrillation and heart failure, we hypothesized that amino terminal pro-B-type natriuretic peptide (NT-proBNP) would identify a subgroup of patients from the Warfarin-Aspirin Recurrent Stroke Study, diagnosed with inferred noncardioembolic ischemic strokes, where anticoagulation would be more effective than antiplatelet agents in reducing risk of subsequent events. Methods-NT-proBNP was measured in stored serum collected at baseline from participants enrolled in Warfarin-Aspirin Recurrent Stroke Study, a previously reported randomized trial. Relative effectiveness of warfarin and aspirin in preventing recurrent ischemic stroke or death over 2 years was compared based on NT-proBNP concentrations. Results-About 95% of 1028 patients with assays had NT-proBNP below 750 pg/mL, and among them, no evidence for treatment effect modification was evident. For 49 patients with NT-proBNP >750 pg/mL, the 2-year rate of events per 100 person-years was 45.9 for the aspirin group and 16.6 for the warfarin group, whereas for 979 patients with NT-proBNP ≤750 pg/mL, rates were similar for both treatments. For those with NT-proBNP >750 pg/mL, the hazard ratio was 0.30 (95% confidence interval: 0.12-0.84; P=0.021) significantly favoring warfarin over aspirin. A formal test for interaction of NT-proBNP with treatment was significant (P=0.01). Conclusions-For secondary stroke prevention, elevated NT-proBNP concentrations may identify a subgroup of ischemic stroke patients without known atrial fibrillation, about 5% based on the current study, who may benefit more from anticoagulants than antiplatelet agents.
KW - Aspirin
KW - NT-proBNP
KW - Secondary stroke prevention
KW - Warfarin
UR - http://www.scopus.com/inward/record.url?scp=84876286491&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84876286491&partnerID=8YFLogxK
U2 - 10.1161/STROKEAHA.112.675942
DO - 10.1161/STROKEAHA.112.675942
M3 - Article
C2 - 23339958
AN - SCOPUS:84876286491
VL - 44
SP - 714
EP - 719
JO - Stroke
JF - Stroke
SN - 0039-2499
IS - 3
ER -